Vornia Biomaterials designs, develops and fabricates customised biomaterial solutions for medical device manufacturers and providers who need to add differentiation to their products in the marketplace.

About Us

Untitled

Vornia is a strong innovative company based in Ireland producing a range of medical biomaterials for the pharmaceutical, cosmetic and medical devices industry. Our innovative team explores the frontier of developing biomaterials to supply this exciting growing market.

Vornia Biomaterials is an innovative SME with accredited expertise in ISO13485 Design and Development. Vornia’s quality management system is based upon:

1. FDA 21 CFR Part 820 (cGMP) guidelines.

2. European Medical device Directive (MDD)93/42/EEC as amended by 2007/47/EC

3. Application of Risk Management as per ISO14971:2012

4. Vornia are certified according to ISO 13485: 2012 since 2013.

Vornia is currently accredited for both, Design and Development and Manufacturing and Supply of raw materials for medical devices targeting the fast growing biomaterials market with a focus on commercializing bio-resorbable synthetic polymers, functionalized polymers and collagen type I.

Vornia supplies a range of high purity bio-resorbable polymers (as powders and granules) including the most common bio-resorbable polymers required in biomedical engineering, both in research and clinical products – poly (ƹ-caprolactone) (PCL), poly (D,L-lactide-co-glycolide) (PLGA), poly (L-lactide) (PLLA), poly (D,L-lactide) (PDLLA), poly (L-lactide-co-ƹ-caprolactone) (PLCL) as well as functionalized polymers including fast-gelling thiol-modified hyaluronic acid (HA-SH), methacrylate modified hyaluronic acid (HA-MA), methacrylate modified gelatin (Gel-MA) and photo-crosslinkable/ chemical-crosslinkable multi-acrylate hyperbranched PEG-polymer (HB-PEG-MAPs/Multiarms PEG).

Vornia’s major strength comes from our synergistic approach to biomaterials chemistry design using innovative processing technologies. Vornia have developed innovative processes that result in higher purity products while eliminating the need, cost and hazardous waste associated with environmentally harmful solvents. The exclusion of solvents from our polymer production offers significant advantages over our competitors’ materials since Vornia’s products are entirely free from immunogenic solvent residues – a USP raising the level of acceptance for Vornia’s polymers in the field of medical applications addressing clinical challenges in various device and pharmaceutical applications. Vornia also maintain a strong research profile in the area of material applications while we currently work towards developing wound care therapies, cardiovascular stents, neural conduits, drug formulations through participation in several FP7 and Horizon 2020 projects (Mozart, Rebiostent, Neurimp, Matrixassay, HyMedPoly).

In addition, Vornia provides a design, development and production service for customized biomaterial solutions especially for medical device manufacturers and providers, but also for academic and industrial clients. Our innovative biomaterial platform technologies also enable the development of polymeric systems for applications in 3D bioprinting, drug and gene delivery with the aim to limit immunogenic responses and or to stimulate integration of the biomaterial into the body.

 

 

More information:
Personnel | Contact Us | Careers | Feedback | Disclaimer